The engineered exosomes displayed tremendous potential to enhance the activation of type one conventional DCs in their original location, subsequently leading to the cross-priming of tumor-reactive CD8+ T cell responses (Figure 7) and resulting in potent inhibition of tumor growth (170). Here, CD8A is linked to neoplasm.